Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making
OncoTargets and Therapy2015Vol. 8, pp. 959–959
Citations Over TimeTop 15% of 2015 papers
Glen J. Weiss, Brandi R. Hoff, Robert P. Whitehead, Ashish Sangal, Susan Gingrich, Robert Penny, David Mallery, Scott Morris, Eric J. Thompson, David Loesch, Vivek Khemka
Abstract
In the current analysis, commercially available NGS platforms provided clinically relevant actionable targets (CA or CT) in 47%-67% of diverse cancer types. In the samples analyzed, PCDx significantly outperformed F1 in TAT, and had statistically significant higher clinically relevant actionable targets categorized as CA.
Related Papers
- → Turn Around Time (TAT) as a Benchmark of Laboratory Performance(2010)94 cited
- → Use of Specimen Turnaround Time as a Component of Laboratory Quality: A Comparison of Clinician Expectations with Laboratory Performance(1989)37 cited
- → Evaluation and Improvement Strategy of Analytical Turnaround Time in the Stat Laboratory(2007)18 cited
- → Laboratory Information Systems and Analytical Turnaround Time(2017)1 cited
- → Analysing Turnaround Time in Laboratory - A Key Performance Indicator(2018)